HLA-B*1502 Strongly Predicts Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain

Pain Practice

Volumn 12, Issue 3, 2012, Pages 202-208

  Kulkantrakorn, Kongkiat ^a   Tassaneeyakul, Wichittra ^b   Tiamkao, Somsak ^b   Jantararoungtong, Thawinee ^b   Prabmechai, Napat ^b   Vannaprasaht, Suda ^b   Chumworathayi, Pansu ^c   Chen, Pei ^d   Sritipsukho, Paskorn ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c Srinagarind hospital   (Thailand)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

1502; Carbamazepine; Genetic markers; HLA B; Neuralgia; Pain; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN; HLA B1502 ANTIGEN; UNCLASSIFIED DRUG; ANALGESIC AGENT;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MALE; NEUROPATHIC PAIN; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; STEVENS JOHNSON SYNDROME; THAILAND; TOXIC EPIDERMAL NECROLYSIS; AGED; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; GENE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NEURALGIA;

ADULT; AGED; ALLELES; ANALGESICS, NON-NARCOTIC; CARBAMAZEPINE; CASE-CONTROL STUDIES; DRUG TOXICITY; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; GENES, MHC CLASS I; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; NEURALGIA; SENSITIVITY AND SPECIFICITY; STEVENS-JOHNSON SYNDROME; THAILAND;

EID: 84863414368     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00479.x     Document Type: Article

References (34)

1. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e1188.
2. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008;71:1183-1190.
3. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol. 1993;32:428-431.
4. Krivoy N, Taer N, Neuman M. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf. 2006;1:289-299.
5. Wolf R, Wolf D, Davidovici B. In the persuit of classifying severe cutaneous adverse reactions. Clin Dermatol. 2007;25:348-349.
6. Roujeau J. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123-129.
7. Chung W, Hung S, Chen Y. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf. 2010;9:15-21.
8. Ding W, Lee C, Choon S. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010;49:834-841.
9. Mehta T, Prajapati L, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75:579-582.
10. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010;51:926-930.
11. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin-induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49:2087-2091.
12. Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav. 2010;19:405-408.
13. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16:297-306.
14. Farkas R. Clinical Review, Adverse Events of Carbamazepine. 2007. Available at [accessed on May 11, 2011].
15. Lim K, Kwan P, Tan C. Association of HLA-B*1502 allele and carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia. 2008;13:15-21.
16. Ferrell PB Jr, McLeod H. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543-1546.
17. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.
18. Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J Clin Psychopharmacol. 2008;28:509-517.
19. Devi K, George S, Criton S, Suja V, Sridevi P. Carbamazepine-the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7years. Indian J Dermatol Venereol Leprol. 2005;71:325-328.
20. Romphruk A, Phongaen K, Chotechai L, Puapairoj C, Leelayuwat C, Romphruk A. HLA-B*15 subtypes in the population of north-eastern Thailand. Eur J Immunogenet. 2003;30:153-158.
21. Kongmaroeng C, Romphruk A, Ruangwerayut R, et al. HLA-B*15 subtypes in Burmese population by sequence-based typing. Tissue Antigens. 2009;74:164-167.
22. Yang G, Deng YJ, Qin H, et al. HLA-B*15 subtypes distribution in Han population in Beijing, China, as compared with those of other populations. Int J Immunogenet. 2010;37:205-212.
23. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99-107.
24. Alfirevic A, Jorgensen A, Williamson P, Chadwick D, Park B, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7:813-818.
25. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617-1622.
26. Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51:2461-2465.
27. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse reactions in Japanese population. Hum Mol Genet. 2011;20:1034-1041.
28. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134-1143.
29. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63:732-741.
30. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology. 2008;71:1527-1534.
31. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11:349-356.
32. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329:168-169.
33. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126-1133.
34. Locharernkul C, Shotelersuk V, Hirankarn N. HLA-B* 1502 screening: time to clinical practice. Epilepsia. 2010;51:936-938.